Tendon Xanthomas Achilles Hypercholesterolemia | DPM

Tendon xanthomas are cholesterol-laden deposits that accumulate within tendon tissue — they are not merely a cosmetic finding but a specific clinical marker for severe hypercholesterolemia, particularly familial hypercholesterolemia (FH), and are associated with dramatically elevated cardiovascular risk. What tendon xanthomas are: xanthomas are deposits of cholesterol and other lipids within macrophage cells (foam cells) in the extracellular matrix of tendons; the Achilles tendon is the most commonly affected because it has the largest cross-sectional area of any tendon and is under tremendous repetitive loading; the Achilles xanthoma presents as: fusiform (spindle-shaped) thickening of the Achilles tendon; the normal Achilles tendon measures 4–6mm in anteroposterior diameter at its midsubstance; xanthomatous Achilles tendons may measure 9–25mm or more; the thickening may be nodular (firm, palpable lumps within the tendon) or diffuse fusiform enlargement; sometimes the overlying skin shows xanthelasma (flat yellowish plaques); the color beneath the skin is yellow (reflecting the lipid content) in contrast to the white, fibrous appearance of normal tendon. What they indicate — a metabolic alarm signal: tendon xanthomas are almost pathognomonic for familial hypercholesterolemia (FH); FH is an autosomal dominant genetic disorder of LDL cholesterol metabolism; untreated FH produces LDL cholesterol levels of 190–400+ mg/dL (normal: under 100 mg/dL); individuals with FH have a 20-fold elevated risk of premature cardiovascular disease; the average age of first heart attack in untreated FH is 43 for men and 53 for women; a patient found to have Achilles tendon xanthomas should receive urgent lipid panel measurement and cardiac risk assessment; the tendon finding itself may be the first physical manifestation that prompts the FH diagnosis.

Tendon xanthoma diagnosis begins with clinical recognition by any examining physician but requires laboratory confirmation and often imaging for complete characterization. Clinical diagnosis: physical examination is the entry point; the Achilles tendon should be palpated in all patients with known hypercholesterolemia and in any patient with unexplained Achilles tendon thickening; findings: palpable nodularity or diffuse thickening of the Achilles tendon; the tendon feels indurated (firm, non-compressible) rather than the normally soft, slightly elastic texture; measurement: the examiner can estimate the AP diameter of the Achilles; greater than 7–8mm in the midsubstance strongly suggests xanthomatous involvement; bilateral involvement is typical of FH (FH is a systemic genetic disease that affects both tendons); extensor tendons of the hand (particularly the extensor digitorum over the metacarpophalangeal joints) and the patellar tendon are other commonly affected sites. Imaging: ultrasound: the most accessible imaging; shows thickening of the Achilles tendon with heterogeneous echogenicity (the xanthoma deposits create areas of increased and decreased reflectivity); can quantify tendon diameter precisely and identify focal nodular deposits within the tendon; MRI: the most sensitive modality for characterizing xanthoma extent; the lipid deposits appear as areas of high T1 signal (bright on T1-weighted images) — the fat content produces this characteristic appearance; useful for planning treatment and quantifying treatment response. Laboratory confirmation: fasting lipid panel: LDL cholesterol is the key measurement; LDL above 190 mg/dL in an adult strongly suggests FH; LDL above 155 mg/dL in a child or adolescent; genetic testing: LDL receptor gene mutation, PCSK9 mutation, and ApoB mutations are identified by genetic panel testing; FH diagnosis can be made by Dutch Lipid Clinic Network or Simon Broome criteria using clinical findings and lab values without genetic testing.

Tendon xanthomas produce direct structural effects on the affected tendons — the cholesterol deposits disrupt normal tendon architecture, reduce tensile strength, and create a chronic inflammatory environment that has significant implications for both tendon pain and the risk of tendon rupture. Tendon pain from xanthomas: Achilles xanthomas produce chronic Achilles tendinopathy symptoms in approximately 40–60% of affected individuals; the pain mechanism: the xanthoma deposits mechanically disrupt the normal parallel collagen fiber architecture of the tendon; lipid-laden macrophages release inflammatory cytokines that chronically stimulate pain receptors in the tendon tissue; the enlarged, thickened tendon is more susceptible to impingement and friction with each step; the chronic inflammation reduces the tendon's capacity to repair micro-damage from normal loading; clinical presentation: the Achilles tendinopathy in FH patients presents similarly to standard Achilles tendinopathy (posterior heel and Achilles pain, worse with first steps of the morning, worsening with high-impact activity) but tends to be more refractory to standard treatment because the underlying cause (lipid accumulation) is not addressed. Rupture risk: individuals with familial hypercholesterolemia and tendon xanthomas have significantly elevated rates of spontaneous tendon rupture compared to the general population; the disrupted collagen architecture reduces the tendon's ability to withstand high tensile loads; spontaneous Achilles rupture (without trauma) is a documented complication of extensive xanthomatous involvement; fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) further weaken xanthomatous tendons and should be avoided if possible in FH patients; the risk of rupture is reduced by aggressive lipid-lowering therapy (statins, PCSK9 inhibitors) which reduces the xanthoma burden and partially restores tendon structure. Important: Achilles tendon xanthomas should not be treated with corticosteroid injection (which further weakens the tendon) without specific indication.

Aggressive lipid-lowering therapy produces measurable reduction in tendon xanthoma size and is associated with improved tendon structure — the treatment of the underlying hypercholesterolemia is the primary treatment for tendon xanthomas, not a surgical approach to the tendons themselves. Evidence for lipid-lowering therapy effects on xanthomas: statin therapy: multiple studies, including serial MRI and ultrasound assessments, demonstrate that high-intensity statin therapy (atorvastatin 40–80mg, rosuvastatin 20–40mg) reduces Achilles tendon xanthoma size measurably over 1–2 years; complete disappearance of xanthomas occurs in some patients with aggressive long-term treatment; partial regression (20–40% reduction in tendon cross-sectional area) is more commonly documented; the structural improvement correlates with LDL cholesterol reduction — achieving LDL below 70 mg/dL (the current target for very high cardiovascular risk in FH) produces the best tendon outcomes; PCSK9 inhibitors (evolocumab, alirocumab): these newer injectable lipid-lowering agents reduce LDL by an additional 50–60% on top of statin therapy; in FH patients who achieve very low LDL levels with combined statin + PCSK9 inhibitor therapy, more rapid and more complete xanthoma regression has been documented in case series; LDL apheresis: for the most severe FH (homozygous FH with extremely high LDL levels refractory to medications), LDL apheresis (a procedure that removes LDL from the blood, similar to dialysis) is used; regular apheresis produces xanthoma regression and dramatically reduces cardiovascular events in this population. What lipid therapy does not achieve: even with optimal lipid lowering, tendon xanthomas may not completely disappear — the fibrotic scarring that accompanies the xanthoma may persist even as the lipid deposits resolve; the chronic tendinopathy symptoms may improve but do not always fully resolve with lipid therapy alone; an integrated approach (lipid lowering + structured tendon rehabilitation for the tendinopathy component) produces the best outcomes.